Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.40 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30154929 | 1.00 | CYP17A1 (0.40) | CYP17A1NOS3NOS2IDO1KDM4E | |
| SCHEMBL21883621 | 0.83 | NOS3 (0.34) | NOS3NOS2KDM4ETLR9TLR8 | |
| SCHEMBL23061556 | 0.79 | IDO1 (0.50) | CYP17A1IDO1KDM4EHTTHTR6 | |
| SCHEMBL928999 | 0.79 | NOS3 (0.45) | CYP17A1NOS3NOS2TLR9TLR8 | |
| SCHEMBL29526095 | 0.79 | NOS3 (0.45) | CYP17A1NOS3NOS2TLR9TLR8 | |
| SCHEMBL19880511 | 0.78 | NOS3 (0.33) | NOS3NOS2 | |
| SCHEMBL27467020 | 0.77 | TLR9 (0.33) | IDO1TLR9TLR8TLR7 | |
| SCHEMBL3668400 | 0.76 | NOS2 (0.52) | CYP17A1NOS3NOS2IDO1KDM4E | |
| SCHEMBL13731405 | 0.76 | CYP17A1 (0.36) | CYP17A1IDO1HTTHTR6 | |
| SCHEMBL16877207 | 0.76 | TLR8 (0.39) | CYP17A1IDO1KDM4EHTTTLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CYP17A1 4465/4885NOS3 4868/4885NOS2 4845/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP17A1 1412/4885NOS3 887/4885NOS2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.